Varma N, O’Donnell D, Bassiouny M, et al. Programming cardiac resynchronization therapy for electrical synchrony: reaching beyond left bundle branch block and left ventricular activation delay. J Am Heart Assoc. 2018;7:e007489. https://www.ahajournals.org/doi/10.1161/JAHA.117.007489. Accessed January 14, 2020.
Canadian Cardiovascular Society. Clinical Significance of Electromechanical Dyssynchrony and QRS Narrowing in Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. http://doi.org/10.1016/j.cjca.2018.10.019. Accessed February 25, 2019.
Okafor O, Leyva F, Zegard A, et al. Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias. J Am Heart Assoc. 2019;8:e013539. DOI:10.1161/JAHA.119.013539.
Niazi, et al. Safety and efficacy of multipoint pacing in cardiac resynchronization therapy—the multipoint pacing trial. JACC: Clinical Electrophysiology. Volume 3, Issue 13, 26 December 2017, Pages 1519-1522. https://doi.org/10.1016/j.jacep.2017.06.022. Accessed January 14, 2020.
Musaad AMA, Bokhari F, Sweidan R, et al. Long term effect of MultiPoint Pacing in Heart Failure patients on end systolic volume: preliminary results from a randomized and multicenter study in the Middle East. APHRS presentation, 2019.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.